ロード中...
The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development
Targeted biologic agents have an established role in treating metastatic colorectal cancer (mCRC). Bevacizumab, a recombinant monoclonal antibody against the vascular endothelial growth factor ligand is approved by the U.S. Food and Drug Administration (FDA) for bevacizumab-naïve patients. Cetuximab...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227885/ https://ncbi.nlm.nih.gov/pubmed/20067946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0167 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|